Whale Analyzer
RA Capital Management 13F Holdings and Portfolio Changes
RA Capital Management reported $11.51B in 13F securities for Q2 2026, with 84 positions. Values are as of the report date; option positions, when present, use underlying-security values. This is not complete fund assets or investment performance.
Open interactive portfolioLatest 13F portfolio changes
New or increased positions include ASCENDIS PHARMA A/S (ASND), PARABILIS MEDICINES (PBLS), HEMAB THERAPEUTICS HOLDINGS (COAG), and ARTIVA BIOTHERAPEUTICS (ARTV). Reduced or exited positions include ASCENDIS PHARMA A/S - ADR (ASND), EDGEWISE THERAPEUTICS (EWTX), DIANTHUS THERAPEUTICS (DNTH), and GH RESEARCH (GHRS). These are comparisons between reported positions, not a record of execution dates, prices or cash traded.
Latest filing metadata: quarter Q2 2026; report date 2026-06-30; filing date 2026-08-14; disclosure source SEC 13F.
Reported holdings and concentration
RA Capital Management's Q2 2026 13F report contains 84 positions valued at $11.51B. The largest reported holdings include ASCENDIS PHARMA A/S, PARABILIS MEDICINES, RHYTHM PHARMACEUTICALS, VAXCYTE, and SIONNA THERAPEUTICS.
The three largest positions in the holdings table account for approximately 37.1% of reported 13F value. The largest reported sector exposure is Health Care at 79.3% of the disclosed portfolio.
The filing metadata lists report date 2026-06-30, filing date 2026-08-14, SEC accession 0001104659-26-097251. SEC 13F reports are normally published up to 45 days after quarter end, so the data is best used to understand institutional positioning after the fact rather than to infer today's exact portfolio.
RA Capital Management portfolio analytics
the top five positions account for 46.7% of disclosed value; the largest sector exposure is Health Care at 79.3%.
Top reported holdings
| Holding | Reported value | Weight | Quarter change |
|---|---|---|---|
| ASND whale holders ASCENDIS PHARMA A/S | $2.74B | 23.8% | New |
| PBLS whale holders PARABILIS MEDICINES INC | $791.9M | 6.9% | New |
| RYTM whale holders RHYTHM PHARMACEUTICALS INC | $740.2M | 6.4% | Held |
| PCVX whale holders VAXCYTE INC | $667.0M | 5.8% | Held |
| SION whale holders SIONNA THERAPEUTICS INC | $435.7M | 3.8% | Held |
| TYRA whale holders TYRA BIOSCIENCES INC | $389.6M | 3.4% | Held |
| EWTX whale holders EDGEWISE THERAPEUTICS INC | $341.0M | 3.0% | Reduced |
| NAMS whale holders NEWAMSTERDAM PHARMA CO NV | $323.7M | 2.8% | Held |
| COAG whale holders HEMAB THERAPEUTICS HOLDINGS | $286.8M | 2.5% | New |
| SEPN whale holders SEPTERNA INC | $234.3M | 2.0% | Held |
New and increased positions
Largest reported position values among additions; not amounts spent buying.
- ASND whale holders — ASCENDIS PHARMA A/S ($2.74B)
- PBLS whale holders — PARABILIS MEDICINES INC ($791.9M)
- COAG whale holders — HEMAB THERAPEUTICS HOLDINGS ($286.8M)
- ARTV whale holders — ARTIVA BIOTHERAPEUTICS INC ($174.2M)
- ABVX whale holders — ABIVAX SA-ADR ($150.9M)
- ORKA whale holders — ORUKA THERAPEUTICS INC ($148.0M)
Reduced and exited positions
Sorted by reported position value; exits use the prior report. These are not sale proceeds.
- ASND whale holders — ASCENDIS PHARMA A/S - ADR ($2.35B)
- EWTX whale holders — EDGEWISE THERAPEUTICS INC ($341.0M)
- DNTH whale holders — DIANTHUS THERAPEUTICS INC ($219.2M)
- GHRS whale holders — GH RESEARCH PLC ($205.3M)
- NUVL whale holders — NUVALENT INC-A ($153.9M)
- PRAX whale holders — PRAXIS PRECISION MEDICINES I ($120.4M)
Allocation
- Health Care: 79.3%
- Other: 20.4%
- Information Technology: 0.3%
- Financials: 0.1%
Data notes
Report date: 2026-06-30
Disclosure source: SEC 13F
Read the original SEC filing (0001104659-26-097251)
SEC 13F filings are delayed public disclosures and do not include every asset class, short positions, or real-time trades.
Related investor portfolios
Profiles with the same disclosure type, ordered by overlap among their top 20 reported holdings.
- Perceptive Advisors 13F holdings and portfolio changes — Perceptive Advisors
- OrbiMed Advisors 13F holdings and portfolio changes — OrbiMed Advisors
- Baker Bros. Advisors 13F holdings and portfolio changes — Baker Bros. Advisors
- Duquesne Family Office 13F holdings and portfolio changes — Duquesne Family Office
- Abrams Bison Investments 13F holdings and portfolio changes — Abrams Bison Investments
- Abrams Capital Management 13F holdings and portfolio changes — Abrams Capital Management
- AKO Capital 13F holdings and portfolio changes — AKO Capital
- Akre Capital Management 13F holdings and portfolio changes — Akre Capital Management
Learn more in Whale Analyzer Academy
Learn more in Whale Analyzer Academy:
Questions about this 13F filing
What does RA Capital Management report for Q2 2026?
The filing reports 84 positions and $11.51B in 13F securities. The holdings table shows reported values and weights; option values follow the filing's reporting conventions.
What changed between filings?
New or increased positions include ASCENDIS PHARMA A/S (ASND), PARABILIS MEDICINES (PBLS), HEMAB THERAPEUTICS HOLDINGS (COAG), and ARTIVA BIOTHERAPEUTICS (ARTV). Reduced or exited positions include ASCENDIS PHARMA A/S - ADR (ASND), EDGEWISE THERAPEUTICS (EWTX), DIANTHUS THERAPEUTICS (DNTH), and GH RESEARCH (GHRS).
Do these amounts show how much was bought or sold?
No. The change lists are ranked by reported position value. Exited positions use their value in the prior report. These amounts are not execution prices, cash invested or sale proceeds.
Is this the current portfolio?
No. Form 13F is a quarter-end snapshot, generally filed within 45 days of quarter end. It excludes short positions and does not cover every asset. Compare the report date and filing date before using the data.